Mevalonolactone

Synonyms: 甲瓦龙酸内酯
Mevalonolactone 是真核生物甲羟戊酸通路中的中间代谢物,也是甲羟戊酸稳定的 δ-内酯形式,具有口服活性,具有 ZNF384 结合亲和力 (Ka = 12.6 μM) 和乌头酸酶 (aconitase) 抑制活性,可促进 ZNF384 核定位并增强其对 GGPPS 启动子的结合作用,诱导胰岛素抵抗,干扰糖脂代谢,增强 K-Ras 的异戊烯基化,并抑制胰岛素信号通路的激活,还可抑制分离大鼠肝细胞中 HMG-CoA reductase 的多肽合成、促进其降解并降低酶活性,损伤大鼠脑线粒体功能,促进代谢不健康型肥胖的发生发展,可用于代谢异常型肥胖、甲羟戊酸尿症、HMGCR 相关的肢带型肌病以及他汀类药物诱导的肌病的相关研究。
产品编号: MS-G56651 纯度: 98.0% CAS No.: 19115-49-2 分子式: C6H10O3 分子量: 130.14
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Mevalonolactone 是真核生物甲羟戊酸通路中的中间代谢物,也是甲羟戊酸稳定的 δ-内酯形式,具有口服活性,具有 ZNF384 结合亲和力 (Ka = 12.6 μM) 和乌头酸酶 (aconitase) 抑制活性,可促进 ZNF384 核定位并增强其对 GGPPS 启动子的结合作用,诱导胰岛素抵抗,干扰糖脂代谢,增强 K-Ras 的异戊烯基化,并抑制胰岛素信号通路的激活,还可抑制分离大鼠肝细胞中 HMG-CoA reductase 的多肽合成、促进其降解并降低酶活性,损伤大鼠脑线粒体功能,促进代谢不健康型肥胖的发生发展,可用于代谢异常型肥胖、甲羟戊酸尿症、HMGCR 相关的肢带型肌病以及他汀类药物诱导的肌病的相关研究。

生物实验数据

生物活性 Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway and the stable δ-lactone form of mevalonic acid, is orally active, exhibits ZNF384 binding affinity (Ka = 12.6 μM) and aconitase inhibitory activity, promotes ZNF384 nuclear localization and enhances its binding to the GGPPS promoter, induces insulin resistance, interferes with glucolipid metabolism, enhances K-Ras prenylation, and inhibits activation of the insulin signaling pathway, and also inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces enzyme activity, impairs rat brain mitochondrial function, promotes the development and progression of metabolically unhealthy obesity, and can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy.
体外研究
(In Vitro)

Mevalonolactone 可直接与重组 ZNF384 蛋白结合,其 Kd 值为 12.6 μM。
Mevalonolactone (1 μM; 24 h) 可增强 AML12 细胞中 K-Ras 的异戊烯化及膜定位,上调细胞中 GGPPS 的蛋白水平,抑制胰岛素刺激 AKT 磷酸化。
Mevalonolactone 处理可促进培养细胞中 ZNF384 的核定位,增强细胞中 ZNF384 与 Ggpps 启动子的结合。
Mevalonolactone (1 mM; added 50 seconds pre-Ca2+, measurements 100 seconds post-Ca2+) 可降低负载 Ca2+ 的大鼠脑线粒体的线粒体膜电位。
Mevalonolactone (1 mM; added 50 seconds pre-Ca2+, measurements 100 seconds post-Ca2+) 可降低 Ca2+ 负载大鼠脑线粒体中的线粒体基质 NAD (P) H 含量,诱导负载 Ca2+ 的大鼠脑线粒体发生肿胀,降低大鼠脑线粒体的 Ca2+ 保留能力。
Mevalonolactone (1-2 mM; 30-minute incubation at 37°C) 可诱导大鼠脑线粒体发生脂质过氧化,显著升高 MDA 水平,抑制大鼠脑线粒体中的乌头酸酶活性。
Mevalonolactone (1 μM-10 mM; 5 min-3 h) 可特异性降低大鼠肝细胞中 HMG-CoA 还原酶的活性。

Western Blot Analysis

Cell Line: AML12 murine hepatocytes
Concentration: 1 μM
Incubation Time: 24 h
Result: Significantly upregulated GGPPS protein levels in AML12 cells.
体内研究
(In Vivo)

Mevalonolactone (10 mM;腹腔注射;每 2 天 1 次;持续 6 周) 可诱导饲喂普通饲料的雄性 C57BL/6J 小鼠发生代谢异常型肥胖,通过上调 GGPPS、增强 K-Ras 异戊烯化以及 ZNF384 介导的 Ggpps 转录激活,引发胰岛素抵抗、葡萄糖稳态受损、体重及组织重量增加、甘油三酯水平升高,以及肝脏和脂肪组织基因表达改变。
Mevalonolactone (10 mM;腹腔注射;每 2 天 1 次;持续 6 周) 可加重高脂饮食喂养的雄性 C57BL/6J 小鼠的胰岛素抵抗及糖脂代谢紊乱,促进代谢不健康型肥胖。
Mevalonolactone (200 mg/kg;口服;每日给药;连续 14 天) 可显著减轻 C57BL/6 小鼠中他汀类药物诱导的肌病症状,使其肌肉力量、耐力及自主活动能力恢复至接近对照组水平。

Animal Model: C57BL/6J (male, 8 weeks old)
Dosage: 10 mmol/L
Administration: i.p.; every 2 days; 6 weeks
Result: Increased area under curve for insulin tolerance.
Increased area under curve for glucose tolerance.
Elevated fasting and postprandial blood glucose levels.
Increased body weight, liver weight to body weight ratio, inguinal white adipose tissue weight to body weight ratio, and epididymal white adipose tissue weight to body weight ratio.
Elevated serum and liver triglyceride levels.
Increased lipid accumulation in liver (observed via H&E and Oil Red O staining).
Upregulated hepatic gene expression of Fasn, Scd1, Srebp1c, Cd36, Gpat, and Dgat.
Downregulated hepatic gene expression of Atgl and Hsl.
Reduced hepatic pyruvate levels and Hk1 expression.
Inhibited insulin-stimulated AKT phosphorylation in the liver.
Upregulated lipogenesis genes (Fasn, Scd1) in inguinal white adipose tissue.
Downregulated lipolysis-related genes and impaired insulin signaling in epididymal white adipose tissue.
Upregulated 284 hepatic genes and downregulated 412 hepatic genes, with enrichment in insulin response, fatty acid transport, cholesterol synthesis, and insulin signaling pathways (FoxO, PI3K-AKT, AMPK).
Increased membrane localization and prenylation of K-Ras.
Upregulated hepatic GGPPS protein and mRNA levels.
Promoted nuclear localization of ZNF384 and enhanced its binding to the Ggpps promoter.
Animal Model: C57BL/6J (male, 8 weeks old, high-fat diet-fed for 8 weeks prior to treatment and throughout treatment)
Dosage: 10 mmol/L
Administration: i.p.; every 2 days; 6 weeks
Result: Reduced insulin sensitivity and disrupted glucose homeostasis.
Increased body weight gain, liver weight, inguinal white adipose tissue mass, and epididymal white adipose tissue mass compared to high-fat diet controls.
Upregulated hepatic gene expression of Fasn, Scd1, Srebp1c, Gpat, Agpat, and Dgat.
Downregulated hepatic gene expression of Cpt1a, Hsl, and Abhd5.
Animal Model: C57BL/6 (8 weeks old)
Dosage: 200 mg/kg/d
Administration: p.o.; daily; 14 days
Result: Improved grip strength, hanging wire performance, total movement, ambulatory movement, voluntary wheel max speed, wheel time sum, wheel runs sum, and wheel total distance significantly compared to cerivastatin alone.
Improved grip strength, hanging wire performance, total movement, ambulatory movement, and voluntary wheel runs sum significantly compared to simvastatin alone.
Showed no overt signs of necrosis or inflammation in diaphragm, gastrocnemius, or quadriceps muscle histology.
性状 液体(密度:1.190±0.06 g/cm3)
颜色 Colorless to light yellow

化学信息

分子量 130.14
分子式 C6H10O3
CAS No. 19115-49-2
别名 甲瓦龙酸内酯

储存&溶解度

储存方式

Store at room temperature, keep dry and cool

In solvent -80°C 1 year
-20°C 6 months
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : ≥ 100 mg/mL (768.40 mM)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM7.6840 mL38.4202 mL76.8403 mL192.1008 mL
5 mM1.5368 mL7.6840 mL15.3681 mL38.4202 mL
10 mM0.7684 mL3.8420 mL7.6840 mL19.2101 mL
15 mM0.5123 mL2.5613 mL5.1227 mL12.8067 mL
20 mM0.3842 mL1.9210 mL3.8420 mL9.6050 mL
25 mM0.3074 mL1.5368 mL3.0736 mL7.6840 mL
30 mM0.2561 mL1.2807 mL2.5613 mL6.4034 mL
40 mM0.1921 mL0.9605 mL1.9210 mL4.8025 mL
50 mM0.1537 mL0.7684 mL1.5368 mL3.8420 mL
60 mM0.1281 mL0.6403 mL1.2807 mL3.2017 mL
80 mM0.0961 mL0.4803 mL0.9605 mL2.4013 mL
100 mM0.0768 mL0.3842 mL0.7684 mL1.9210 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础